慢性尼古丁降低了尼格拉的多巴胺活性,并重塑了pedunculopontine胆固醇亚群
bioRxiv : the preprint server for biology
|February 23, 2026
概括
慢性尼古丁可以通过改变神经元活动来预防帕金森病. 它减少了多巴胺神经元的发射,并修改了胆固醇神经元的功能,潜在地提高了脆弱的大脑细胞的弹性.
科学领域:
- 神经科学是一个神经科学.
- 神经生物学 神经生物学 神经生物学
- 细胞生理学 细胞生理学
背景情况:
- 流行病学研究表明,尼古丁可以降低帕金森病 (PD) 风险,但其细胞机制尚不清楚.
- 在PD中脆弱的多巴胺和胆神经元表现出独特的特性,有助于神经退行.
- 慢性尼古丁的预防性,但不是治疗效果,需要对其对这些特定神经元群体的影响进行调查.
研究的目的:
- 研究慢性尼古丁对 substantia nigra pars compacta (SNc) 多巴胺基和 pedunculopontine核 (PPN) 胆能神经元的生理和形态影响.
- 阐明尼古丁对PD的神经保护作用的潜在细胞机制.
主要方法:
- 在成年小鼠的急性脑切片中,全细胞补丁电生理学.
- 两光子成像,以评估树突性动态.
- 在口服尼古丁暴露8-10周后进行形态重建以分析神经元结构.
主要成果:
- 慢性尼古丁降低了SNC多巴胺基神经元中的自发心脏节律,爆发倾向和反弹发射.
- 尼古丁脱离了SNC神经元中的近端树突的水平,而没有改变L型通道或突触驱动.
- PPN胆能神经元表现出特定亚区域的可塑性:面向PPN表现出脱极化和树突修剪,而尾部PPN表现出改变的尖端适应和更快的刺激后突触电流.
结论:
- 慢性尼古丁会诱导SNC多巴胺和PPN胆固醇神经元的显著生理变化.
- 这些改变表明尼古丁可能促进神经元性并降低PD风险的机制.
- 这项研究提供了关于尼古丁在神经退行性疾病背景下预防性神经保护作用的细胞洞察力.
更多相关视频
08:47Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
14.0K
10:48Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine
Published on: January 25, 2019
9.8K
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
2.2K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K
CNS Depressants: Alcohol and Nicotine
1.4K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.4K
Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Cholinergic Receptors: Nicotinic
6.0K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
6.0K
Drugs Affecting Neurotransmitter Release or Uptake
1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.3K
